iBrands Corporation Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies

Full Alliance Group, Inc. | The Cutting Edge of Health | > Blog > iBrands Corporation Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies

LAS VEGAS, June 29, 2020 (GLOBE NEWSWIRE) — iBrands Corporation (OTC: IBRC) (“the Company”), a diversified holding and branding company, announces filing of a new patent by nutraceutical product manufacturer Therapeutic Solutions Int’l (TSOI) covering suppression of the indolamine 2,3 deoxygenase (IDO) pathway by QuadraMune™ administration.

In the study, mice were administered lipopolysaccharide (LPS), a compound known to stimulate inflammation, in order to replicate inflammation-associated depression. Mice receiving LPS suffered a reduction in memory activity, as quantified using the Morris Water Maze test.

Administration of QuadraMune™ significantly inhibited inflammation associated with memory impairment, as well as reduced levels of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation and depression [1].

“The current data support the possibility of QuadraMune™ being used as an adjuvant to numerous immune therapies whose efficacy is currently inhibited by the depression-inducing and immune blocking effects of the indolamine 2,3 deoxygenase enzyme,” said Dr. James Veltmeyer, Chief Medical Officer and co-inventor of the current patent. “Many times, when you activate the immune system, cells in the body, and in the brain, start producing the enzyme indolamine 2,3 deoxygenase, whose role is to restrain the immune system, and for reasons unknown, causes depression. By manipulating this enzyme through natural means, we are optimistic that we can enhance the efficacy of numerous immune modulatory treatments for viral and neoplastic conditions.”

Dr. Thomas Ichim, Board Member of Therapeutic Solutions International, has been working on this enzyme since 2013 when he published in the peer-reviewed literature regression of breast cancer using RNA interference to block its expression [2].

“From a commercialization perspective we are truly optimistic about the implications of the current results, which may require us to consider expanding our clinical trial programs,” said Timothy Dixon, President, and CEO of the Company. “The IDO enzymatic pathway is not only extremely interesting from a medical perspective, but companies working on manipulating this pathway have previously entered Big Pharma deals with potential values in excess of $1 billion [3].  In contrast to other programs that utilize synthetic approaches, QuadraMune™, which is comprised of natural ingredients and is available as a nutraceutical, may possess numerous advantages for accelerated commercialization.”

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About iBrands Farms

iBrands Farms is a vertically integrated agribusiness focused on the production of hemp derived products with naturally occurring cannabinoids along with other nutraceutical products. Our mission is to efficiently deliver the highest quality products to our customers, both retail and B2B. 

The company can be found at www.ibrandsfarms.com

About iBrands Corporation

iBrands Corporation, Inc. is a holding and branding company that acquires and operates niche market brands that have unique market positions within sectors that demonstrate return on investment potential. Business partnerships throughout the United States and Canada provide our brands many markets to expand into and produce consistently high growth rates for the next decade. 

The company can be found at: www.ibrandscorporation.com

Safe Harbor Statement
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company’s ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company’s suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.


[1] Lanser et al. Inflammation-Induced Tryptophan Breakdown Is Related With Anemia, Fatigue, and Depression in Cancer. Front Immunol . 2020 Feb 21;11:249. https://www.frontiersin.org/articles/10.3389/fimmu.2020.00249/full

[2] Zheng et al. Silencing IDO in Dendritic Cells: A Novel Approach to Enhance Cancer Immunotherapy in a Murine Breast Cancer Model. Int J Cancer. 2013 Feb 15;132(4):967-77

[3] https://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle 

Source link

Leave a Reply